Skip to content
LinkedInTwitter
gabarx.com Logo
  • Home
  • About Us
  • Our Team
    • Leadership Team
    • Board of Directors
    • Science Board
  • Our Science
  • GRX-917
    • GRX-917
    • GRX-917 History
    • Mechanism of Action
  • Therapeutic Focus
    • Therapeutic Focus
    • Anxiety
    • Neurosteroid Disorders
  • Media
    • News
    • Publications
  • Contact Us
  • Home
  • About Us
  • Our Team
    • Leadership Team
    • Board of Directors
    • Science Board
  • Our Science
  • GRX-917
    • GRX-917
    • GRX-917 History
    • Mechanism of Action
  • Therapeutic Focus
    • Therapeutic Focus
    • Anxiety
    • Neurosteroid Disorders
  • Media
    • News
    • Publications
  • Contact Us

Is GRX-917 Patent Protected?

The Company has used deuteration technology to create a new and improved version of etifoxine, deuterated etifoxine (GRX-917), that has composition of matter patent protection, until 2036.

Richard Farrell2019-09-22T19:30:37+00:00Patent|
Read More

Why Was Etifoxine Never Introduced into the United States?

Early Beginnings The original, non-deuterated drug (etifoxine) was originally developed to compete with tranquilizing and sedative BZs of the 1960’s, such as Valium and Librium. But it was mischaracterized as a mild benzodiazepine, because of its lack of typical benzodiazepine side effects, like sedation and ataxia. Hoechst sold the rights [...]

Richard Farrell2019-09-22T19:29:45+00:00Financial, Patent|
Read More
  • Privacy Policy
  • Terms of Use
Copyright 2021 GABA Therapeutics | All Rights Reserved | GRX-917 is NOT FDA approved.
LinkedInTwitter